Lipid Disorders and Metabolic-Associated Fatty Liver Disease

Shima Dowla Anwar; Christy Foster; Ambika Ashraf

doi:10.1016/j.ecl.2023.01.003

Lipid Disorders and Metabolic-Associated Fatty Liver Disease

Endocrinol Metab Clin North Am. 2023 Sep;52(3):445-457. doi: 10.1016/j.ecl.2023.01.003. Epub 2023 Feb 26.

Authors

Shima Dowla Anwar¹, Christy Foster², Ambika Ashraf³

Affiliations

¹ Department of Pediatrics, Boston Children Hospital, Harvard Medical School, Boston, MA, USA.
² University of Alabama at Birmingham, 1601, 4th Avenue South, CPP M 30, Birmingham, AL 35233, USA.
³ University of Alabama at Birmingham, 1601, 4th Avenue South, CPP M 30, Birmingham, AL 35233, USA. Electronic address: AAshraf@uabmc.edu.

PMID: 37495336
DOI: 10.1016/j.ecl.2023.01.003

Abstract

Dyslipidemia has been linked metabolic-associated fatty liver disease (MAFLD). Several genes and transcription factors involved in lipid metabolism can increase susceptibility to MAFLD. Multiple parallel 'hits' have been proposed for developing hepatic steatosis, NASH, and MAFLD, including insulin resistance and subsequent free fatty acid excess, de novo lipogenesis, and excessive hepatic triglyceride and cholesterol deposition in the liver. This lead to defective beta-oxidation in the mitochondria and VLDL export and increased inflammation. Given the significant cardiovascular risk, dyslipidemia associated with MAFLD should be managed by lifestyle changes and lipid-lowering agents such as statins, fenofibrate, and omega-3 fatty acids, with judicious use of insulin-sensitizing agents, and adequate control of dysglycemia.

Keywords: Dyslipidemia; Eicosapent ethyl; Fibrate; MAFLD; NAFLD; Statin.

Publication types

Review

MeSH terms

Humans
Lipid Metabolism
Lipogenesis
Liver / metabolism
Non-alcoholic Fatty Liver Disease* / complications
Non-alcoholic Fatty Liver Disease* / therapy
Triglycerides / metabolism

Substances

Triglycerides